Please ensure Javascript is enabled for purposes of website accessibility

Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan

By Brian Orelli, PhD – Aug 8, 2020 at 10:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Global expansion is here for the vaccine that's months away from a regulatory approval.

Novavax (NVAX 0.60%) is teaming up with Japanese drug maker Takeda Pharmaceutical (TAK -0.21%) to sell Novavax's coronavirus vaccine, NVX-CoV2373, as a prevention for COVID-19 in Japan.

Takeda will be responsible for manufacturing the protein part of the vaccine and will get some help from Japan's Ministry of Health, Labour and Welfare. The agency has pledged to help fund the manufacturing technology transfer, establishment of infrastructure, and scale-up of manufacturing for the vaccine.

Novavax will be responsible for providing Matrix-M, the adjuvant that's injected with the protein-based vaccine to increase the patient's immune reaction to the viral protein. Early stage results suggested that inclusion of Matix-M resulted in comparable immune reactions, even when the protein part of the vaccine was reduced by a fifth.

Shoulder and a hand carrying a syringe

Image source: Getty Images.

Assuming the vaccine makes its way successfully through the clinical trial process, Takeda will be responsible for regulatory submission of the drug in Japan. If the vaccine is approved in Japan, Takeda expects it can manufacture over 250 million doses of the coronavirus vaccine per year.

Through the deal announced on Friday, Novavax will receive undisclosed payments based on development and commercial milestones, as well as a portion of proceeds from the vaccine.

Unfortunately, without additional details of the deal, it's extremely hard to value Novavax's deal with Takeda. Reading between the lines, though, the deal appears to be signaling that the Japanese drug maker is endorsing Novavax's technology as one of the front-runners in the race to develop the first coronavirus vaccine.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
$16.64 (0.60%) $0.10
Takeda Pharmaceutical Company Stock Quote
Takeda Pharmaceutical Company
$14.55 (-0.21%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.